NURO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NURO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. NeuroMetrix's annualized Gross Profit for the quarter that ended in Dec. 2023 was $3.39 Mil. NeuroMetrix's average Total Assets over the quarter that ended in Dec. 2023 was $21.36 Mil. Therefore, NeuroMetrix's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 15.88%.
The historical data trend for NeuroMetrix's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroMetrix Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 21.51 | 70.52 | 36.02 | 23.21 | 17.13 |
NeuroMetrix Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 20.20 | 19.85 | 19.30 | 14.20 | 15.88 |
For the Medical Devices subindustry, NeuroMetrix's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where NeuroMetrix's Gross-Profit-to-Asset % falls into.
NeuroMetrix's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 3.947 | / | ( (24.67 | + | 21.424) | / 2 ) | |
= | 3.947 | / | 23.047 | ||||
= | 17.13 % |
NeuroMetrix's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | 3.392 | / | ( (21.287 | + | 21.424) | / 2 ) | |
= | 3.392 | / | 21.3555 | ||||
= | 15.88 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of NeuroMetrix's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bradley M Fluegel | director | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Thomas T Higgins | officer: Chief Financial Officer | |
Topline Capital Management, Llc | other: See Explanation in Footnotes | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Topline Capital Partners, Lp | 10 percent owner | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Mcbirney Collin | other: See Explanation in Footnotes | 544 EUCLID STREET, SANTA MONICA CA 90402 |
Shai Gozani | director, officer: Chairman, President and CEO | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Francis X Mcgillin | officer: Senior VP, Consumer | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Avermaete David Van | director | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Krishnamurthy Balachandran | officer: S. VP and GM, International | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Nancy E Katz | director | CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502 |
Neurometrix Inc | officer: Senior Vice President & GM | |
Walter Christensen | officer: Sr. VP, Global Sales | C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
Timothy R Surgenor | director | 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035 |
Deerfield Management Company, L.p. (series C) | 10 percent owner | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Deerfield Mgmt L.p. | 10 percent owner | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By PRNewswire PRNewswire • 06-28-2022
By Marketwired • 07-11-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 03-21-2023
By Marketwired • 07-27-2023
By PRNewswire PRNewswire • 07-08-2022
By PurpleRose PurpleRose • 07-14-2022
By PurpleRose PurpleRose • 07-21-2022
By sperokesalga sperokesalga • 02-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.